WY14,643, a Peroxisome Proliferator-activated Receptor α (PPARα) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice
Open Access
- 1 July 2002
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 277 (27) , 24484-24489
- https://doi.org/10.1074/jbc.m202449200
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Leptin-Replacement Therapy for LipodystrophyNew England Journal of Medicine, 2002
- Lipoatrophy RevisitedTrends in Endocrinology & Metabolism, 2000
- Less Extrahepatic Induction of Fatty Acid β-Oxidation Enzymes by PPARαBiochemical and Biophysical Research Communications, 2000
- Defect in Peroxisome Proliferator-activated Receptor α-inducible Fatty Acid Oxidation Determines the Severity of Hepatic Steatosis in Response to FastingJournal of Biological Chemistry, 2000
- Cellular mechanisms of insulin resistanceJournal of Clinical Investigation, 2000
- Peroxisome proliferator–activated receptor α mediates the adaptive response to fastingJournal of Clinical Investigation, 1999
- Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)Journal of Biological Chemistry, 1998
- Troglitazone action is independent of adipose tissue.Journal of Clinical Investigation, 1997
- Improved glucose tolerance after effective lipid‐lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle’s cycle in its pathogenesis?Clinical Endocrinology, 1997
- Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity.Genes & Development, 1993